Recent Updates in the Treatment Landscape for Advanced Non-Clear Cell Renal Carcinoma

Martin H. Voss, MD, provides an overview of advanced non–clear cell renal cell carcinoma (nccRCC), highlighting epidemiology and pathological classification.

A genitourinary oncologist discusses current treatment options available for patients with non–clear cell renal cell carcinoma and discusses the roles of tyrosine kinase inhibitors (TKIs), PD-1 inhibition, and combination therapy.

Following the 2024 ASCO Annual Meeting, Martin H. Voss, MD, discusses long-term follow-up data from the phase 2 KEYNOTE-B61 trial investigating pembrolizumab plus lenvatinib in the first-line treatment of advanced non–clear cell RCC.

An expert on non–clear cell renal cell carcinoma provides clinical insights on TKI dosing strategies and duration of therapy implications for IO-TKI combinations.

Martin H. Voss, MD, outlines adverse events encountered with different IO-TKI and IO-IO combination regimens in RCC and discusses the importance of open communication with patients.

A genitourinary oncologist discusses the role of multidisciplinary care in the treatment of patients with advanced renal cell carcinoma.

Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.